We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.15B
AUM Growth
-$403M
Cap. Flow
-$229M
Cap. Flow %
-3.73%
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
64
Reduced
62
Closed
12

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$35.2M
2
SYK icon
Stryker
SYK
+$32.7M
3
UNH icon
UnitedHealth
UNH
+$27.9M
4
PODD icon
Insulet
PODD
+$25.5M
5
RMD icon
ResMed
RMD
+$25.5M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$56.7M
2
ARGX icon
argenx
ARGX
+$45.6M
3
INSM icon
Insmed
INSM
+$43.4M
4
BSX icon
Boston Scientific
BSX
+$42.4M
5
HUM icon
Humana
HUM
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Industrials 0.05%
3 Communication Services 0.02%
4 Technology 0.02%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
126
DELISTED
Blueprint Medicines
BPMC
$550K 0.01%
5,100
– –
RYTM icon
127
Rhythm Pharmaceuticals
RYTM
$7.17B
$534K 0.01%
13,000
+500
+4% +$20K
PTGX icon
128
Protagonist Therapeutics
PTGX
$8.77B
$525K 0.01%
15,146
-4,000
-21% -$117K
ZTS icon
129
Zoetis
ZTS
$31.5B
$510K 0.01%
2,941
-4,569
-61% -$760K
AAPL icon
130
Apple
AAPL
$4.88T
$463K 0.01%
2,200
– –
ALKS icon
131
Alkermes
ALKS
$8.83B
$434K 0.01%
18,000
-6,144
-25% -$151K
RCKT icon
132
Rocket Pharmaceuticals
RCKT
$355M
$424K 0.01%
19,700
– –
AMRX icon
133
Amneal Pharmaceuticals
AMRX
$5.75B
$399K 0.01%
62,760
+17,373
+38% +$110K
XENE icon
134
Xenon Pharmaceuticals
XENE
$6.29B
$398K 0.01%
10,200
-3,900
-28% -$156K
ADMA icon
135
ADMA Biologics
ADMA
$1.9B
$345K 0.01%
30,900
-10,000
-24% -$83.9K
FDMT icon
136
4D Molecular Therapeutics
FDMT
$538M
$330K 0.01%
15,700
– –
BBIO icon
137
BridgeBio Pharma
BBIO
$16.6B
$324K 0.01%
12,800
– –
BCYC
138
Bicycle Therapeutics
BCYC
$275M
$324K 0.01%
16,000
+3,500
+28% +$79.1K
DVAX
139
DELISTED
Dynavax Technologies
DVAX
$309K 0.01%
27,558
– –
MDGL icon
140
Madrigal Pharmaceuticals
MDGL
$12.6B
$308K 0.01%
1,100
+40
+4% +$9.52K
VTRS icon
141
Viatris
VTRS
$20.1B
$282K ﹤0.01%
26,531
+12,016
+83% +$133K
CCCC icon
142
C4 Therapeutics
CCCC
$383M
$266K ﹤0.01%
57,600
– –
NKE icon
143
Nike
NKE
$62B
$264K ﹤0.01%
+3,500
New +$325K
VKTX icon
144
Viking Therapeutics
VKTX
$4.08B
$233K ﹤0.01%
4,400
-1,000
-19% -$65.6K
KURA icon
145
Kura Oncology
KURA
$909M
$206K ﹤0.01%
+10,000
New +$206K
MLYS icon
146
Mineralys Therapeutics
MLYS
$2.38B
$205K ﹤0.01%
17,499
+8,299
+90% +$105K
IDYA icon
147
IDEAYA Biosciences
IDYA
$3.47B
$200K ﹤0.01%
5,700
+2,400
+73% +$95K
ETNB
148
DELISTED
89bio
ETNB
$198K ﹤0.01%
24,700
+11,000
+80% +$98.2K
MLTX icon
149
MoonLake Immunotherapeutics
MLTX
$1.59B
$193K ﹤0.01%
4,400
– –
TEM
150
Tempus AI
TEM
$7.92B
$175K ﹤0.01%
+5,000
New +$153K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q2 2024 Portfolio in Review

As of Q2 2024, Bellevue Group held 178 positions worth $6.15B, down 6.1% from $6.56B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $229M in Q2 2024, closing 12 positions and reducing 62 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Edgewise Therapeutics worth $25.7M.

  • Bellevue Group's largest Q2 2024 buy was Edgewise Therapeutics: 1,428,929 shares worth $25.7M.
  • Bellevue Group added most to Biohaven in Q2 2024, an estimated $35.2M increase.
  • Bellevue Group's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $56.7M.
  • Bellevue Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $34.4M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.15B portfolio in Q2 2024.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2024.
  • Bellevue Group's portfolio value fell 6.1% quarter-over-quarter to $6.15B.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.